Registered title, quoted from ClinicalTrials.gov
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
An open trial on Wilson disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07240896, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Patinets with Wilson's disease confirmed by laboratory tests to have double-chromosome mutations in the ATP7B gene.
Inclusion criterion 3
Other liver-related diseases and clinical symptoms that can cause liver injury, such as acute and chronic hepatitis, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, liver cirrhosis, liver ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, liver failure, liver malignancy, etc.; Subjects with Model for end-stage liver disease score (MELD)>13.
Exclusion criterion 4
The subjects are atable patients with WD who have been trasted for at least six months without drug or dose changes for at least 6 momths at the time of screening , and have continuously used standard treatments [SOC, such as D-penicillamine, sodiu dihydroxypropane sulfonate, dimercaptosuccinic acid, trientine, and zinc preparations (zinc acetate, zinc gluconate, zinc sulfate)] for at least 6 months screening, and allowed subjects to continue with their prior SOC treatment.
Inclusion criterion 6
ALT < 2 times of upper limit of normal value (ULN);
Inclusion criterion 10
Hemoglobin < 90 g/L;
Exclusion criterion 8
Creatinine clearance ≤30 mL/min, or glomerular filtration rate <45 mL/min/1.73 m²;
Exclusion criterion 9
TBil≥2×ULN,ALP/TBil<4,AST/ALT>2.2;
Exclusion criterion 10
Platelets < 70 ×10\^9/L;
Exclusion criterion 11
Neutrophils < 1.0 × 10\^9 /L.
Exclusion criterion 12
Pregnant women or lactating women.
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07240896, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years old, gender not limited.
- Meet the diagnostic criteria f Wilson's Disease in "Guidelines for Diagnosis and Treatment of Wilson's Disease (2022 Edition)", with a Leipzig score ≥4, at least one year between diagnosis and screening; ceruloplasmin level <0.1g/L.
- Patinets with Wilson's disease confirmed by laboratory tests to have double-chromosome mutations in the ATP7B gene.
- Low copper diet for at least six months befoer screening and willing to continue low copper diet during study.
- Fertile subjects agreed to adopt reliable contrraceptive methods from the screening until 6 months after the last administration.
- The subjects are atable patients with WD who have been trasted for at least six months without drug or dose changes for at least 6 momths at the time of screening , and have continuously used standard treatments [SOC, such as D-penicillamine, sodiu dihydroxypropane sulfonate, dimercaptosuccinic acid, trientine, and zinc preparations (zinc acetate, zinc gluconate, zinc sulfate)] for at least 6 months screening, and allowed subjects to continue with their prior SOC treatment.
- The subject's condition was fully controlled after treatment, and its definition must meet all of the following conditions:
- Serum NCC level ≥ 25 μg/L and ≤ 150 μg/L;
- Urinary copper ≥100 μg/24 hours and ≤900 μg/24 hours;;
- ALT < 2 times of upper limit of normal value (ULN);
- The investigator believes that no other laboratory values or clinical symptoms would stop current standard therapy;
- Subjects with good compliance, who can understand and cooperate to complete the requirements of protocol.
- The subjects voluntarily participated in the trial and signed the informed consent form.
Exclusion Criteria:
- Allergy or intolerance to the investigational drug.
- Wilson's disease is accompanied by severe complications such as neurological and mental disorders.
- History of liver transplantation.
- Other liver-related diseases and clinical symptoms that can cause liver injury, such as acute and chronic hepatitis, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, liver cirrhosis, liver ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, liver failure, liver malignancy, etc.; Subjects with Model for end-stage liver disease score (MELD)>13.
- Other diseases that can cause hemolysis or anemia, such as erythrocytosis, Mediterranean anemia, hemolytic anemia, various causes of infection, large area burns, etc.
- Other diseases that can cause dysfunction of the nervous system, such as Parkinson's disease, Parkinson syndrome, various causes of dystonia, chorea, primary tremor, epilepsy, mental abnormalities (such as history of schizophrenia or suicide attempts), etc.
- Screening period laboratory examination indicators:
- Hemoglobin < 90 g/L;
- Creatinine clearance ≤30 mL/min, or glomerular filtration rate <45 mL/min/1.73 m²;
- TBil≥2×ULN,ALP/TBil<4,AST/ALT>2.2;
- Platelets < 70 ×10\^9/L;
- Neutrophils < 1.0 × 10\^9 /L.
- History of gastrointestinal bleeding within six months before screening.
- Subjects with history of moderate to severe depression, suicidal thoughts or behaviors and serious psychiatric within 6 months prior to screening.
- Subjects who have uncontrolled diseases of thr heart, liver, kidneys, endocrine system, digestive tract, metabolism, blood, or malignant tumors.
- Active hepatitis B virus infection or active hepatitis C virus infection, or human immunodeficiency virus antibody positive.
- Pregnant women or lactating women.
- Subjects who have participated other clinical trial within 3 months prior to screening or plan to participate during the clinical trial.
- Investigators evaluate other subjects who are not suitable to participate in this clinical trial.
Quoted from ClinicalTrials.gov, NCT07240896, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07240896, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.